Pharma in will performance our to assets. quarter XXXX. progress we of will the and by the been Lennart. our segments able on including with meaning Hello, you, everyone. and segment. Thank you testing take update second begin the I business, will what core financials, you during commercial company then have René COVID-XX you our then Diagnostics of the and its walking our achieve insights through provide you operational further into key Today, I through Clinical
for outlook. We we guidance open financial will then will provide and for our up Afterwards, Q&A. the XXXX business
to turn X. please Let's Slide
Let me our quarter in meaningful a outlined priorities, event first which delivered the today. strong made on for and at key progress our We top line the strategic June. highlight messages on we investor
This Patrice As on a Chief from data-driven approach delivered excited on seeing the reinventing most where reflects quarter. mentioned management continuously the contribution our board in XX%. year-over-year and revenue Scientific growth a from the our I'm see of revenues our added to Since still million for and new of drug very with have the our the at perspective, most we who further drug strong return team. and the core with Patrice business testing. growth COVID-XX strong are But €XX we in the surpassing as our We we event, will in performance importantly, Officer, of we very June, team expanding Denèfle, are development. have lead development. discovery to addition recent to discovery efforts
are We operating EBITDA segment see also all adjusted to positive in pleased segments.
in Our is having a This with our added Bio/Databank XX,XXX new X growth towards increase also our goal patients in QX million steady demonstrated approximately XXXX. of patients Bio/Databank.
XX% growth, focused shown over genes the on offer to seen we different have XX,XXX tests. business the diagnostic solid this segment, using diseases, We committed broadest We to up we currently over that have diagnostics. return superior XX,XXX covering offering year-over-year. are Within rare portfolio testing
to compounding segment, and growth. are our In growing the indicated we continuously business We last to value continuing this the leverage Bio/Databank. the leading in to have quarters, and to continue it's the trend nice see Pharma steady of
stream. reflects XX half of We the is end first value revenue year-over-year, active the the for of in exceeds in of the XXXX collaborations believe this already year contract and revenue now quarter, signed down of our XXXX. have kind alone we While what lumpiness full the signed this we
the to remains expansion on continues. underline XXXX the Overall, partnership believe firm pharma disease business focus want and our I of that contract our rare for beyond. we So in core
the indicative belief across Pharma We business segments foundation the will to of towards a years. of recovery in This of year. strong the of both growth is end built set in rare against second and our strong business diseases year. This the of the of the statement cure solid our XXX in our core half enabling reflected be have are mission deliver the XX within next
Please the us discuss Let X. Slide now turn company's detail. performance to in
more revenues driven our QX by to for COVID-XX a million increase [XXXX]. core compared which strong in of was quadrupled as accounted which Our well This than includes recovery testing, as QX Diagnostics €XX.X Pharma. XXXX and business,
XX% €X.X million. grew business to by core Our
the trends As business core end a of pandemic segments, towards this second recap, in we impacted The experienced the headwinds gradually and business XXXX. our particularly from that last the year quarter core early COVID-XX year. recovered
order One communicated which calls. of was CENTOGENE prior at investors trends, looking at the earning intake ways the we
We to in QX trends are XXXX, Pharma in revenue Diagnostics in €X.X €X.X versus €X.X to and now €X.X last that compared pleased XXXX. million million year-over-year increased revenues to segment QX reaching confirm report million QX decreased million from the see Diagnostics XX% that recovery year.
a for towards longer on cycle, are deals On time. in we calls, a revenue we Pharma top accelerating lumpy. of believe rebuilding our fully on We of business segment sales study test in takes has and the aiming partnership recruit the of value intact. collaboration with Pharma to prior for with To XXXX, ROPAD, extended the identification global pioneer prioritized the Takeda. extended patients mutations and discussed As the more CENTOGENE's cognizant of that key and signed genetic a initiated is in Parkinson's LRRKX with Parkinson’s CENTOGENE the the recruitment in contract We quick accelerate first half XXXX, Parkinson's, for year of genetically that, XXXX, first with entered targeted recovery patients disease of with and frontotemporal X,XXX new into of Alector But disease. to one also diagnosis a the in that diseases. recap In immune-neurology based disease update Denali provide gene. dementia global remains patients the business so of neurodegenerative strategic collaboration half our momentum the the additional end Therapeutics we view pipeline of
Parkinson’s, currently So lead deal. errors longitudinal ongoing biomarkers, observational this studies observational expansion of several as And metabolism. amyloidosis part and covering to of we is inborn such clinical XX disease transthyretin categories and validate/monitor that
the I'm we will into in Pharma. solid return XXXX, also confident not fully So in as core we of half look that to ahead growth, only but second Diagnostics,
business, our in XX%. turn Now please to number X. is up of meaning sample Pharma order and Diagnostics The Slide intakes core
period Given XX% the requests same the versus and test well the which where we progress were samples was XXXX. cell revenue, Bio/Databank, are discussed driven Pharma lines. includes increase growth up our data on making as business, Overall, Diagnostics by the in as in growing
on the right, individuals On see in the repository. graph you our the of data number
provide the disease-centric to is almost in core we I which an added course will on update in rare database later. XXXX, first of Over our this X biobank, our XX,XXX asset. individuals quarters the
Slide to X. Turning
ramped have our Bio/Databank, our R&D growing initiatives. up also we to addition In
but and in these rare how mere also discuss just are we have and like by in would Parkinson's diagnostics well development. and in our a advancements and for focused technology. momentum We as is of publishing growth this insights exponential our for generation sequencing to and excellence numbers the diseases, alone striving shows published milestone to in reached papers, author not The XXX basis XX use reflected years continuous on leadership insight X recently differentiated QX a graph as reputations critical peer-reviewed scientific which into drug XXXX disease as generating scientific genetic past papers in of including we the
in part Our Sets scientific creating clearly impact. is us. progress publication the in
published research over which leveraging which rare the of patients discovery and advanced immediately diseases new X are have from enable to diagnostic diagnosis led data our XX to incorporated biobank. existing We offering our now by of
technology launched our a the complexity unlocking at Exome around have Sequencing from of unique Whole by an XX% coupling aiming NEW CentoXome, core Whole enhanced the commitment up diseases omics compared On Exome world, to better possible Sequencing. disease-centric increases our rare yields side, rare diagnosis to the contribution superior the which called to patients enable diseases product and our with view development. conventional Bio/Databank best of understanding differentiated rare to We drug we to provide the insights orphan diagnostic
connecting core turn rare of understanding by aim world Slide the do connecting around the to revolutionize At their our patients is X. biology. of what Let's to the diseases and we
the and us unique different asset, of have quality have continuously This We for data. both an in the cases today Bio/Databank as to managed our value terms volume shown we grow of creation. address use how allows to
considering in nearly But a the XXX,XXX that doing more specific each genomics, has of on able also prioritizing. a date, known. diseases high how X,XXX genetic we is which that to rare currently at into of look been is of we Now going specific accumulate have diseases data have our number beyond and samples take If rare X and deeper in it diseases translates mentioned. numbers, remarkably have been have been also link we Bio/Databank grown over to this depth. already depth we only testing In subset actually diagnosed
more million variants. includes Our mutation than CentoMD database XX
Bio/Databank the valuable as cohorts For can and patient for their identification support, insights we patient is diseases on geographies. trial of provide certain
and than We They're that all. Again, XX rare that's over at XXX number low have diseases a patients XXX very about prevalence. least high a with diagnosed considering patients. with rare diseases have more XXX after
of Our XX,XXX with large last physicians physician the contracts couple network over also active encompasses years.
companies things disease. for us working rare #X add up make life science world's rare disease of these the partner on and All
On complexities We this while the novel drug segments, medical to core supports biology we Slide and a in by allows believe and this target other the other data-driven identification for of Overall, reason, treat in us And structure and a Bio/Databank patients’ like of disease well to turn as to the spectrum, we really rare discovery no grow drug development. solutions. in company discovery our as approach. partner driving XX. choice as Please development. understand unlock are both end orphan believe acting of positioned
our very I'm C analyze data outstanding sphere. improving manage approach an much genetic approaches development, with discovery well Denèfle expertise one unprecedented as and data, of Initially, record patient unique proven will disease Parkinson's to scientific deep up With And data-driven to scientific sets people but to industry, who CENTOGENE. drug derived reinvent to constantly in intelligence Niemann-Pick on ramp for way data artificial data Patrice Officer. neurological as successfully is Patrice and combine the industry Scientific and leader track tools, our and stability on our has disorders. are Patrice are to appointed credentials work Chief unique with in To and our his and only data-driven his few available be metabolomic data to We drug development. applied work rare discovery to as diseases, for the public patients. Gaucher the we in X cell accelerate not public an we Patrice Type looking forward focusing and and the in
in In on be and model achieving of Looking is diseases a will to to lines areas the cell models. patients and diseases with diagnosed to the XX more data able XXX full to XXX to disease disease base for the discover Full strategically biomarkers. data expand be set cure further for range future, XX XXX and develop in next validation our we to years. will to targets druggable full this, enabled we focus XX and omics us in these
us to please turn Slide XX. Let
we confident quick ecosystem believe Lastly, positioned we I recap we would on in provide a delivering our in why mission. rare like are feel the against to why disease uniquely and
one rare We very the we building first unique solid I genetic in companies disease stayed been asset base. we are testing starting have a course, the from world, over believe many and a the of years.
a that a and for recognized strong that. are the world We is are as around brand, leading we genomic expert disease rare now respected
And together eventually we to the of their relies believe differentiate for the we pioneers panel Asia multi-omics because followed have also Bio/Databank, this truly insight. is genetic to prevalent approach rare multi-omics by Middle for further metabolic that geographies strive ensuring past the And are a on and companies insights, needed. rare multi-omic not who think our analysis particularly curation diagnostics and are doing important a new diagnose global testing only patients. we as we that us and thus market, with as ecosystem the to started research Bringing have We the certain is stored have rare samples, genetic cutting-edge parts just in insights available. market bring diagnosis become and the of new this diseases. this to player together, was access before, us tools of bringing and some omics, unique genetic to have also we really our testing be footprint from for better diseases onto today access constantly for East improving to strong the insights. our products discussed like allowing high-income detailed phenotypical truly where much done able to been or footprint, country. later activities, into global diseases, data-driven importantly, With multi our one or And putting believe we in the on develop focused can benefits in positions patients may physicians CentoMetabolic, areas And a diagnosis but while we
world. compare comprehensive Bio/Databank see the we a hand rare can think disease you lead generations we financials We focused me that to and detail. insights companies really tools, on rare through are data walk sense more the in the and are and in within to you. fully the let the that truly You René in mining can means table. have most we geographic the that presence René, that over to we that have disease, said, over unique around that With ourselves
